These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7690177)

  • 21. [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
    Tamaki M; Ueda T; Kageyama S
    Hinyokika Kiyo; 1999 Dec; 45(12):827-30. PubMed ID: 10659415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of an alpha 1-adrenergic blocker (prazosin HCl) on micturition disturbances associated with benign prostatic hypertrophy.
    Shimizu K; Nakai K; Imai K; Yamanaka H
    Urol Int; 1990; 45 Suppl 1():36-9. PubMed ID: 1690479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical effect of allylestrenol on benign prostatic hypertrophy].
    Tajima A; Aso Y; Ushiyama T; Hata M; Kambayashi T; Ohmi Y; Masuda H; Nakahara M; Kitagawa M; Suzuki A
    Hinyokika Kiyo; 1986 Mar; 32(3):477-85. PubMed ID: 2425610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prazosin in benign prostatic hypertrophy.
    Rowden AM; Mowers RM
    DICP; 1989 Jun; 23(6):474-5. PubMed ID: 2472708
    [No Abstract]   [Full Text] [Related]  

  • 25. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
    Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
    Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Using setegis (terasosine) in early postoperative period after transurethral prostate resection].
    Teodorovich OV; Zabrodina NB; Bochkarev AB
    Urologiia; 2009; (3):62-4. PubMed ID: 19673124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M; Ramsdell J; Young J; McNicholas T
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prazosin in patients with benign prostatic obstruction.
    Hedlund H; Andersson KE; Ek A
    J Urol; 1983 Aug; 130(2):275-8. PubMed ID: 6192252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study.
    Yamaguchi O; Shiraiwa Y; Kobayashi M; Yokota T; Ohinata M; Aoki H; Tsuzuki T; Ohori M
    Urol Int; 1990; 45 Suppl 1():40-6. PubMed ID: 1690481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
    Yang MG; Zhao XK
    Zhonghua Nan Ke Xue; 2007 Sep; 13(9):830-4. PubMed ID: 17929564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prazosin in the treatment of patients with adenoma of the prostate gland].
    Pytel' IuA; Mashkovskiĭ MD; Vinarov AZ; Zhirinkova ML; Kaminka ME
    Sov Med; 1988; (9):31-5. PubMed ID: 2463677
    [No Abstract]   [Full Text] [Related]  

  • 39. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future.
    Clarke DE
    Br J Urol; 1998 Jul; 82(1):167. PubMed ID: 9698692
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.